Veeva Systems, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Rhyee from TD Cowen maintained a Hold rating on the stock and has a $297.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Rhyee has given his Hold rating due to a combination of factors including the mixed financial results and future outlook of Veeva Systems. The company showed solid performance in its second fiscal quarter, particularly in its Crossix and R&D segments, which were positive indicators for its business momentum. However, the stock experienced a decline in the market following a slight miss in billings for the second quarter and a conservative billing guidance for the third quarter, which were below market expectations.
Management attributed the billing discrepancies to changes in customer billing terms aligning with the calendar year budget cycle, which affected short-term perceptions. Despite these challenges, there is optimism surrounding Veeva’s partnership with IQVIA, which could unlock future growth opportunities, although no immediate revenue impact is expected. The analyst also noted that while the macroeconomic environment remains uncertain, the pipeline is building, and the company raised its fiscal year 2026 billing guidance. These mixed signals contributed to the Hold rating, reflecting a cautious but optimistic outlook.
Rhyee covers the Healthcare sector, focusing on stocks such as CVS Health, Evolent Health, and Veeva Systems. According to TipRanks, Rhyee has an average return of 1.8% and a 48.69% success rate on recommended stocks.
In another report released on August 21, Truist Financial also reiterated a Hold rating on the stock with a $268.00 price target.